Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 22, 2020

Sunovion gets FDA nod for Kynmobi to treat Parkinson’s disease off episodes

Sunovion Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Kynmobi (apomorphine hydrochloride) sublingual film (APL-130277) to treat Parkinson’s disease (PD) off episodes.

Sunovion has secured FDA approval for Kynmobi to treat Parkinson’s disease off episodes. (Credit: Sunovion Pharmaceuticals Inc.)